An international panel of nutrition and geriatrics specialists argues that low-grade micronutrient and omega-3 insufficiency is a widespread, cheap-to-fix, and badly under-recognised driver of unhealthy ageing. Their case runs through mitochondria: B vitamins, iron, copper, zinc, selenium and vitamins A, C, D and E sit at the catalytic heart of energy production and antioxidant defence, so chronic shortfall degrades ATP output, raises reactive oxygen species, and feeds the inflammageing and immunosenescence loop that damages muscle, brain, kidney, heart and immune tissue. Because organ function begins declining in the fifth decade, the authors propose a blood micronutrient panel at around age 50, repeated every four to five years, with targeted correction only where deficiency or suboptimal status is documented. They explicitly reject blanket multivitamin use for everyone, and they concede the trial evidence is inconsistent: thirteen positive randomised trials sit alongside twenty-five mixed or neutral and five frankly negative ones.
The multivitamin debate has been stuck for two decades. One camp publishes editorials titled “enough is enough, stop wasting money on vitamin and mineral supplements.” The other points to trial after trial where correcting a shortfall improved something measurable. Berger and colleagues, writing in GeroScience, try to break the deadlock by changing the question. Instead of asking whether supplements work for everyone, they ask who is actually deficient, and what specifically breaks when they are.
The big idea is that micronutrients are not drugs and should stop being tested like drugs. A statin lowers cholesterol in a roughly dose-proportional way in almost anyone who takes it. Zinc does not work that way. Zinc is a structural cofactor for superoxide dismutase; once you have enough, more does nothing, and considerably more may do harm. Nutrients follow U-shaped curves, not straight lines. Testing them in populations that already have adequate status is, in the authors’ framing, a design error rather than a negative result, and it explains why so many large trials have landed on null.
The mechanism they build the argument around is mitochondrial. Every step from glucose to ATP depends on specific micronutrients: thiamine and B6 for the entry reactions, riboflavin and niacin to build the FAD and NAD carriers, iron and copper for the respiratory chain cytochromes. Selenium, zinc, manganese and copper then run the antioxidant enzymes that mop up the electron leak. Let those slip and you get less energy, more oxidative damage, more mitochondrial DNA mutation, impaired mitophagy, and release of damage-associated molecular patterns that trigger inflammasomes. That is a plausible and well-supported route from an unremarkable blood test to sarcopenia, cognitive decline and frailty.
Three things make the shortfall common rather than exotic. Ageing guts absorb less, especially B12, as intrinsic factor production falls. Restrictive diets, whether vegan, low-carbohydrate or heavily ultra-processed, systematically strip out particular nutrients. And ordinary medications interfere: proton pump inhibitors block B12, vitamin C and iron; metformin depletes B9 and B12; diuretics flush water-soluble vitamins; statins impair selenoprotein synthesis and coenzyme Q10.
The proposal is a midlife blood panel covering the B vitamins, C, D, E, K, iron, selenium, zinc and the erythrocyte omega-3 index, read alongside CRP because inflammation drags micronutrient readings down independently of true status. Correct what is low. Leave the rest alone. The authors are candid that no evidence yet shows such screening improves hard outcomes, and that assay standardisation between laboratories remains poor.
Actionable Insights
The honest headline is that benefits are real but mostly small, and largest in people who start deficient.
The clearest wins are in people with a documented shortfall. In people with mild cognitive impairment and high homocysteine, two years of B6, B12 and folate cut brain shrinkage from 1.08 to 0.76 percent per year, about a 30 percent reduction. In early macular degeneration, zinc plus antioxidants reduced progression by roughly 28 percent.
Now the reality check on general use. In COSMOS, a daily multivitamin improved global cognition by 0.07 standard deviations. A standard deviation is the natural spread of scores in a population, so 0.07 of one is a change you would never notice in yourself, even though the study detected it reliably. Anything under 0.2 counts as small. Multivitamins cut total cancer risk by about 8 percent over 11 years in male physicians, with the statistical margin scraping the edge of no effect at all.
Practical takeaways: get B12, vitamin D, ferritin, zinc, selenium and an omega-3 index measured, especially if you are over 50, on a proton pump inhibitor or metformin, or eating a restrictive diet. Correct what is genuinely low. Avoid high-dose single antioxidants, particularly vitamin E, where excess has caused harm. [Confidence: Medium for targeted repletion, Low for general supplementation]
Context and Source
- Open Access Paper: Micronutrients and omega-3 PUFAs to promote healthy ageing: informing a physiology-based complementation strategy
- Article type: Opinion Paper, narrative expert synthesis
- Authors and institutions: Mette M. Berger (University of Lausanne, Switzerland, corresponding), with co-authors from Stellenbosch University (South Africa), University of Lausanne Hospital CHUV (Switzerland), Colorado State University (USA), Linus Pauling Institute at Oregon State University (USA), University of Alberta (Canada), University of Basel (Switzerland), and University of Southampton and NIHR Southampton Biomedical Research Centre (UK)
- Lead country: Switzerland, with a multinational author panel
- Journal: GeroScience (Springer Nature, official journal of the American Aging Association)
- Funding and conflicts: Nestlé (Vevey, Switzerland) funded two author meetings and supported the graphical design via PorterHouse Medical. The authors nonetheless declare no competing interests. Readers should weigh that themselves.
- Impact evaluation: The impact score of this journal is 6.0 (2025 Journal Impact Factor; five-year JIF 6.2; SJR 1.468; h-index 87; Q1 in Ageing and in Geriatrics and Gerontology), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal. It is a well-regarded specialist venue within geroscience,